Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer.
The contribution of genetic variants in RhoA and ROCK1 genes towards prostate cancer risk has not been reported before. We genotyped six potentially functional genetic variants in a case-control study of 1699 subjects. Overall, we found rs2410 mutant allele and rs2269736 wild allele were risk factors for prostate cancer. Individuals carrying more than two risk alleles were exposed to hazard of prostate cancer. In addition, we demonstrated that the risk of biochemical recurrence might be linked with clinico-pathological characteristics and also genetic factors. Unfortunately, no associations were observed between all polymorphisms and clinico-pathological characteristics. Moreover, no genotype was found as significant independent prognostic predictor for biochemical recurrence survival in Multivariate Cox regression analysis after Bonferroni correction. Our study is the first to clarify the relations of genetic variants of RhoA and ROCK1 genes with development, progression and prognosis of prostate cancer. These variants may be promising novel biomarkers to facilitate clinical treatment decision-making.
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Kang
K
Liu
Department of Urology, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China.
Xiao
X
Li
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jie
J
Wang
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yichun
Y
Wang
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Huiyu
H
Dong
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jie
J
Li
D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D018450:Disease Progression; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000473:pathology; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*; D012307:Risk Factors; D015996:Survival Rate; D054460:rho-Associated Kinases / Q000235:genetics*; D020742:rhoA GTP-Binding Protein / Q000235:genetics*
D014408:Biomarkers, Tumor; C066737:RHOA protein, human; C515851:ROCK1 protein, human; D054460:rho-Associated Kinases; D020742:rhoA GTP-Binding Protein
RhoA/ROCK1 pathway; biochemical recurrence; genetic variants; prognosis; prostate cancer